Intercure Ltd. (INCR) — SEC Filings
Intercure Ltd. (INCR) — 23 SEC filings. Latest: 6-K (Dec 30, 2025). Includes 21 6-K, 2 20-F.
View Intercure Ltd. on SEC EDGAR
Overview
Intercure Ltd. (INCR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Nov 3, 2025: On November 3, 2025, InterCure Ltd. announced a strategic investment and collaboration with Cannasoul to advance cannabis science and pharmaceutical innovation. This partnership aims to leverage both companies' expertise to develop new products and research in the cannabis sector.
Sentiment Summary
Across 23 filings, the sentiment breakdown is: 3 bullish, 20 neutral. The dominant filing sentiment for Intercure Ltd. is neutral.
Filing Type Overview
Intercure Ltd. (INCR) has filed 21 6-K, 2 20-F with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (23)
Risk Profile
Risk Assessment: Of INCR's 18 recent filings, 0 were flagged as high-risk, 9 as medium-risk, and 9 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Key Executives
- Ehud Barak
- Alexander Rabinovich
- Amos Cohen
- Rami Levy
Industry Context
Intercure Ltd. operates within the pharmaceutical preparations industry, indicated by its SIC code 2834. This sector involves the manufacturing of drugs and medicines.
Top Tags
shareholder-meeting (7) · corporate-governance (6) · pharmaceuticals (3) · cannabis (2) · financial-results (2) · revenue (2) · acquisition (2) · leadership-change (2) · financing (2) · meeting-adjournment (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Revenue | NIS 130 Million | First half 2025 revenue reported |
| ISHI Acquisition | 100% | InterCure aims to acquire full ownership of ISHI. |
| Initial Share Purchase | 50% | The first phase of the acquisition involves purchasing 50% of ISHI's shares. |
| Fiscal Year End | 2024 | The report covers the financial performance up to December 31, 2024. |
| Prior Fiscal Year End | 2023 | Comparative financial data is provided for the year ending December 31, 2023. |
| Earlier Fiscal Year End | 2022 | Comparative financial data is also provided for the year ending December 31, 2022. |
| Maximum Funding | USD 29.8M | Potential capital infusion for InterCure Ltd. |
| Initial Funding | USD 18.2M | Secured funding amount as of December 19, 2024 |
| Proposals Approved | 8 | All proposals presented at the Extraordinary General Meeting were approved by shareholders. |
| Filing Date | 2024-05-01 | The date the 20-F was submitted to the SEC. |
| SIC Code | 2834 | Industry classification for Pharmaceutical Preparations. |
| 2023 Preliminary Revenue | NIS 351 million | Indicates the company's top-line performance for the fiscal year. |
| 2023 Preliminary EBITDA | over NIS 50 million | Shows the company's operational profitability before interest, taxes, depreciation, and amortization. |
Frequently Asked Questions
What are the latest SEC filings for Intercure Ltd. (INCR)?
Intercure Ltd. has 23 recent SEC filings from Jan 2024 to Dec 2025, including 21 6-K, 2 20-F. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of INCR filings?
Across 23 filings, the sentiment breakdown is: 3 bullish, 20 neutral. The dominant sentiment is neutral.
Where can I find Intercure Ltd. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Intercure Ltd. (INCR) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Intercure Ltd.?
Financial highlights for Intercure Ltd. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for INCR?
The investment thesis for INCR includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Intercure Ltd.?
Key executives identified across Intercure Ltd.'s filings include Ehud Barak, Alexander Rabinovich, Amos Cohen, Rami Levy.
What are the main risk factors for Intercure Ltd. stock?
Of INCR's 18 assessed filings, 0 were flagged high-risk, 9 medium-risk, and 9 low-risk.
What are recent predictions and forward guidance from Intercure Ltd.?
Forward guidance and predictions for Intercure Ltd. are extracted from SEC filings as they are enriched.